MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 581644 | Name: Primycin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Primycin has strong antituberculotic characteristics, belongs to the group of Sakaguchi-positive antibiotics.

Chemical Structure

Primycin
CAS#30003-49-7

Theoretical Analysis

MedKoo Cat#: 581644

Name: Primycin

CAS#: 30003-49-7

Chemical Formula: C110H208N6O38S

Exact Mass: 2253.4249

Molecular Weight: 2254.94

Elemental Analysis: C, 58.59; H, 9.30; N, 3.73; O, 26.96; S, 1.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Primycin; Debrycin sulfate; Ebrimycin; Primycin A(sub 1) sulfate; Primycin A1 sulfate.
IUPAC/Chemical Name
Guanidine, (5-(19-(alpha-D-arabinofuranosyloxy)-35-butyl-10,12,14,16,18,22,26,30,34-nonahydroxy-3,5,21,23-tetramethyl-36-oxooxacyclohexatriaconta-4,20-dien-2-yl)-4-hydroxyhexyl)-, sulfate (2:1) salt
InChi Key
DBULPBHLGBAFFN-XRGRGHKRSA-N
InChi Code
InChI=1S/2C55H103N3O17.H2O4S/c2*1-7-8-19-43-45(67)20-12-18-37(60)16-11-17-38(61)23-22-33(3)49(69)34(4)26-47(73-54-51(71)50(70)48(31-59)74-54)46(68)30-42(65)29-41(64)28-40(63)27-39(62)15-10-9-14-32(2)25-35(5)52(75-53(43)72)36(6)44(66)21-13-24-58-55(56)57;1-5(2,3)4/h2*25-26,33,35-52,54,59-71H,7-24,27-31H2,1-6H3,(H4,56,57,58);(H2,1,2,3,4)/b2*32-25-,34-26+;/t2*33?,35?,36?,37?,38?,39?,40?,41?,42?,43?,44?,45?,46?,47?,48-,49?,50-,51+,52?,54+;/m11./s1
SMILES Code
NC(NCCCC(O)C(C(C(C)/C=C(C)\CCCCC(O)CC(O)CC(O)CC(O)CC(O)C(O[C@@H]1[C@H]([C@@H]([C@@H](CO)O1)O)O)/C=C(C)/C(O)C(C)CCC(O)CCCC(O)CCCC(O)C2CCCC)OC2=O)C)=N.NC(NCCCC(O)C(C(C(C)/C=C(C)\CCCCC(O)CC(O)CC(O)CC(O)CC(O)C(O[C@@H]3[C@H]([C@@H]([C@@H](CO)O3)O)O)/C=C(C)/C(O)C(C)CCC(O)CCCC(O)CCCC(O)C4CCCC)OC4=O)C)=N.O=S(O)(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 2,254.94 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pénzes Á, Mahmud Abdelwahab EM, Rapp J, Péteri ZA, Bovári-Biri J, Fekete C, Miskei G, Kvell K, Pongrácz JE. Toxicology studies of primycin-sulphate using a three-dimensional (3D) in vitro human liver aggregate model. Toxicol Lett. 2017 Nov 5;281:44-52. doi: 10.1016/j.toxlet.2017.09.005. Epub 2017 Sep 13. PubMed PMID: 28916286. 2: Feiszt P, Schneider G, Emődy L. Effect of primycin on growth-arrested cultures and cell integrity of Staphylococcus aureus. Acta Microbiol Immunol Hung. 2017 Jun 1;64(2):121-130. doi: 10.1556/030.64.2017.002. Epub 2017 Mar 6. PubMed PMID: 28263102. 3: Valasek A, Kiss ÍÉ, Fodor I, Kovács M, Urbán P, Jámbor É, Fekete C, Kerepesi I. Proteomic insight into the primycin fermentation process of Saccharomonospora azurea. Acta Biol Hung. 2016 Dec;67(4):424-430. doi: 10.1556/018.67.2016.4.8. PubMed PMID: 28000508. 4: Hong H, Samborskyy M, Lindner F, Leadlay PF. An Amidinohydrolase Provides the Missing Link in the Biosynthesis of Amino Marginolactone Antibiotics. Angew Chem Int Ed Engl. 2016 Jan 18;55(3):1118-23. doi: 10.1002/anie.201509300. Epub 2015 Dec 2. PubMed PMID: 26630438; PubMed Central PMCID: PMC4737276. 5: Feiszt P, Mestyán G, Kerényi M, Dobay O, Szabó J, Dombrádi Z, Urbán E, Emődy L. Re-evaluation of in vitro activity of primycin against prevalent multiresistant bacteria. Int J Med Microbiol. 2014 Nov;304(8):1077-85. doi: 10.1016/j.ijmm.2014.08.001. Epub 2014 Aug 12. PubMed PMID: 25179867. 6: Nyilasi I, Kocsubé S, Krizsán K, Galgóczy L, Papp T, Pesti M, Nagy K, Vágvölgyi C. Susceptibility of clinically important dermatophytes against statins and different statin-antifungal combinations. Med Mycol. 2014 Feb;52(2):140-8. PubMed PMID: 24004389. 7: Virág E, Belagyi J, Kocsubé S, Vágvölgyi C, Pesti M. Antifungal activity of the primycin complex and its main components A1, A2 and C1 on a Candida albicans clinical isolate, and their effects on the dynamic plasma membrane changes. J Antibiot (Tokyo). 2013 Feb;66(2):67-72. doi: 10.1038/ja.2012.103. Epub 2012 Nov 21. PubMed PMID: 23168406. 8: Kovács P. [Tibor Vályi-Nagy (1912-1969), professor and researcher of pharmacology, was born one hundred years ago]. Orv Hetil. 2012 Jun 3;153(22):869-72. doi: 10.1556/OH.2012.HO2411. Hungarian. PubMed PMID: 22641263. 9: Virág E, Juhász A, Kardos R, Gazdag Z, Papp G, Pénzes A, Nyitrai M, Vágvölgyi C, Pesti M. In vivo direct interaction of the antibiotic primycin on a Candida albicans clinical isolate and its ergosterol-less mutant. Acta Biol Hung. 2012 Mar;63(1):38-51. doi: 10.1556/ABiol.63.2012.1.4. PubMed PMID: 22453799. 10: Virág E, Pesti M, Kunsági-Máté S. Complex formation between primycin and ergosterol: entropy-driven initiation of modification of the fungal plasma membrane structure. J Antibiot (Tokyo). 2012 Apr;65(4):193-6. doi: 10.1038/ja.2011.140. Epub 2012 Jan 25. PubMed PMID: 22274705. 11: Virág E, Belagyi J, Gazdag Z, Vágvölgyi C, Pesti M. Direct in vivo interaction of the antibiotic primycin with the plasma membrane of Candida albicans: an EPR study. Biochim Biophys Acta. 2012 Jan;1818(1):42-8. doi: 10.1016/j.bbamem.2011.09.020. Epub 2011 Sep 29. PubMed PMID: 21978596. 12: Virág E, Pesti M, Kunsági-Máté S. Competitive hydrogen bonds associated with the effect of primycin antibiotic on oleic acid as a building block of plasma membranes. J Antibiot (Tokyo). 2010 Mar;63(3):113-7. doi: 10.1038/ja.2009.130. Epub 2010 Jan 15. PubMed PMID: 20075979. 13: Nyilasi I, Kocsubé S, Pesti M, Lukács G, Papp T, Vágvölgyi C. In vitro interactions between primycin and different statins in their effects against some clinically important fungi. J Med Microbiol. 2010 Feb;59(Pt 2):200-5. doi: 10.1099/jmm.0.013946-0. Epub 2009 Oct 29. PubMed PMID: 19875509. 14: Szabó A, Kónya A, Széll V, Máté G, Erdélyi B. Biological and chemical detections in adsorbent layer for monitoring microbial production of primycin. J Chromatogr Sci. 2007 Aug;45(7):435-8. PubMed PMID: 17725871. 15: Papp T, Ménesi L, Szalai I. Experiences in the Ebrimycin gel treatment of burns. Ther Hung. 1990;38(3):125-8. PubMed PMID: 2284621. 16: Suga'r IP, Blaskó K, Györgyi S, Shcagina LV, Malev VV, Lev AA. Cooperative binding of primycin and gramicidin on erythrocyte membranes. A cation transport study. Membr Biochem. 1989;8(1):1-10. PubMed PMID: 2478862. 17: Bálint G. Favourable observations with Ebrimycin gel in the outpatient department of surgery. Ther Hung. 1987;35(3):140-2. PubMed PMID: 3438875. 18: Bíró J, Várkonyi V. Ebrimycin gel in the treatment of pyodermas and bacterial secondary infections. Ther Hung. 1987;35(3):136-9. PubMed PMID: 3438874. 19: Mészáros C, Vezekényi K. Use of Ebrimycin gel in dermatology. Ther Hung. 1987;35(2):77-9. PubMed PMID: 3438866. 20: Blaskó K, Shagina LV, Györgyi S, Lev AA. The mode of action of some antibiotics on red blood cell membranes. Gen Physiol Biophys. 1986 Dec;5(6):625-36. PubMed PMID: 2435616.